



Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025

October 7, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY study in patients with pre-cirrhotic (F2-F3) MASH.

Details for the presentations are as follows:

Oral Presentations

Title: Efruxifermin was associated with improvements in multiple non-invasive tests indicative of fibrosis regression in participants with compensated cirrhosis due to MASH (SYMMETRY)

Presenter: Vlad Ratziu, M.D., Ph.D., Professor of Hepatology, Sorbonne Université and the Hôpital Pitié-Salpêtrière Medical School

Session: Clinical Plenary #1

Date/Time: Sunday, November 9, 2025, 12:00 PM ET

Title: Efruxifermin improved markers of portal hypertension as evaluated by Baveno VII criteria in compensated cirrhosis due to MASH: results from a 96-week, placebo-controlled, phase 2b trial

Presenter: Mazen Nouredin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute

Session: MASH Clinical Trials

Date/Time: Sunday, November 9, 2025, 2:45 PM ET

Poster Presentation

Title: AI-powered histology analysis of HARMONY reveals Efruxifermin-driven changes in the liver microarchitecture in F2/F3 MASH

Presenter: Jörn M. Schattenberg, M.D., Professor of Medicine, Director of the Department of Medicine, Saarland University Medical Center, University of Saarland

Session: MASLD/MASH Therapeutics: New Agents and Approved / Available Agents

Date/Time: Monday, November 10, 2025, from 11:30 AM-12:30 PM ET

About Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero's lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY *Histology* in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY *Outcomes* in patients with compensated cirrhosis (F4c) due to MASH, and SYNCHRONY *Real-World* in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on [LinkedIn](#) and [X](#) for more information.

Investor Contact:

Christina Tartaglia

Precision AQ

212.362.1200

IR@akerotx.com

Media Contact:

Peg Rusconi

Deerfield Group

617.910.6217

Peg.rusconi@deerfieldgroup.com